Market capitalization | $601.77m |
Enterprise Value | $629.93m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4,845.62 |
P/S ratio (TTM) P/S ratio | 4,629.00 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 15.94% |
Revenue (TTM) Revenue | $130.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Opthea Limited - ADR forecast:
5 Analysts have issued a Opthea Limited - ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.13 0.13 |
18%
18%
|
|
Gross Profit | 0.02 0.02 |
-
|
|
EBITDA | -193 -193 |
-
|
EBIT (Operating Income) EBIT | -193 -193 |
29%
29%
|
Net Profit | -221 -221 |
56%
56%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
Head office | Australia |
CEO | Frédéric Guerard |
Founded | 1984 |
Website | www.opthea.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.